Advancements in Pancreatic Cancer Vaccines and Treatments.

A clinical trial has reported promising results from testing a personalized approach to boosting immune responses to pancreatic tumours. Pancreatic cancers generally don’t respond to immune-checkpoint inhibitors (ICIs) because they express lower levels of neoantigens than other types of tumours, and thus are less likely to activate a strong immune response from antitumour T cells. However, the trial found that a vaccine that boosts T cells that target neoantigens in pancreatic tumours could be effective in treating the disease.